LETTER FROM THE CHAIRMAN

As chairman of the Alzheimer’s Drug Discovery Foundation (ADDF), it is my pleasure to share with you the progress we have made towards finding new ways to diagnose, prevent, and treat Alzheimer’s disease.

The reason that I have taken on the challenge of trying to find an early cure for Alzheimer’s is that it is an insidious disease that each year strikes some 35 million people worldwide (with more than 115 million people estimated to develop it by 2050)—with no hope of survival. I have made it my mission in life to find the drugs for its prevention and cure within the next ten years.

I am looking for partners who can join me to support the drugs that are poised to cure this disease but don’t have the funding to support their preclinical and clinical testing. Our Foundation’s partnership model has worked extraordinarily well, as we are able to multiply by many the number of drugs that can be tested.

Should you be interested in learning more about how we are able to carry out our approach, please do not hesitate to contact our Executive Director, Dr. Howard Fillit. He will be happy to meet with you or any of your medical advisors to walk you through our model. Ours is a unique one that may be worth a few minutes of your time to examine.

Simply stated, no one is addressing the challenge of drug development the way the ADDF is. We will win this battle!

Leonard A. Lauder
Chairman
LETTER FROM THE EXECUTIVE DIRECTOR

2010 was a year of tremendous growth for the Alzheimer’s Drug Discovery Foundation. We saw a surge in requests for funding and provided critical support to help researchers continue their efforts to develop new therapies for Alzheimer’s disease. Here are some key statistics from 2010:

- We reviewed over 250 grant proposals – 60% more than in 2009.
- The ADDF provided more than $6.5 million in new funding to 37 highly deserving research programs. This was a significant increase over the $3.8 million we granted in 2009 and allowed us to not only fund more programs, but to also provide larger grants to worthy programs.
- Thanks to our generous donors, the ADDF raised a record $8.6 million in 2010 – a 56% increase over funds raised in 2009.
- More than 20% of our grants were awarded to international research programs in Australia, the Netherlands, Sweden, Spain, and Switzerland.

We saw impressive progress in many of the programs that we supported. For example:

- Avid Radiopharmaceuticals, Inc. continued its development of a critically needed brain imaging test to help diagnose Alzheimer’s disease. The test contains a novel imaging agent, called Florbetapir, which was developed by researchers at the University of Pennsylvania with startup funding of $350,000 from the ADDF from 2000 to 2003.
Letter from the Executive Director (continued)

- Metabolic Solutions Development Company is beginning a human clinical trial to evaluate the effectiveness of its novel drug, Mitoglitazone, in treating Alzheimer’s disease. The drug, which was initially developed as a treatment for diabetes, improves metabolism in the mitochondria – the energy powerhouse of the cell. The ADDF helped fund preclinical research demonstrating the drug’s potential to prevent the buildup of beta-amyloid plaques associated with Alzheimer’s disease. The ADDF will continue to support the clinical development of this drug through our new Program to Accelerate Clinical Trials (PACT).

In addition, the ADDF continues to provide grants to researchers who are exploring novel approaches for treating Alzheimer’s disease:

- With the help of a grant from the ADDF, Carmela Abraham, PhD, and her team from the Boston University School of Medicine have identified several compounds that increase brain levels of an anti-aging protein called Klotho. Dr. Abraham’s team is swiftly evaluating these compounds for their potential to slow Alzheimer’s disease progression.

- AgeneBio Inc. is using ADDF funding to develop novel therapies that may counteract overactivity in the region of the brain that is responsible for memory function. Intervening during the earliest stages of Alzheimer’s disease may help to preserve more memory. Read more about these and other exciting projects we are funding in our “Profiles of Progress” (page 7).
During the past year, the ADDF also developed new programs and initiatives that will strengthen our ability to evaluate and fund the most promising Alzheimer’s research projects, from preclinical studies through human clinical development:

- In partnership with Charles River Discovery & Imaging Services/Cerebricon Ltd., the ADDF convened an advisory panel to develop consensus guidelines to improve the design of preclinical studies of potential Alzheimer’s disease therapies, and to standardize the reporting of data from these studies. These guidelines were presented in March 2011 at the 10th International Conference on Alzheimer’s and Parkinson’s Disease in Barcelona, Spain. The guidelines will be published in a peer-reviewed scientific journal in 2011.

- We created and launched our Program to Accelerate Clinical Trials (PACT), which provides funding for clinical development of novel therapies for Alzheimer’s disease. In 2010, PACT raised more than $2 million and supported three early-stage clinical trials. This targeted program will build on the ADDF’s previous funding of more than 20 clinical trials.

In the coming year, we look forward to an increasingly vigorous fundraising effort, so that we can provide support to the ever increasing number of worthy new grant applications. The ADDF plays a vital role in accelerating the discovery and development of new Alzheimer’s treatments. With your continued support, we will realize our goal of preventing, treating, and ultimately curing Alzheimer’s disease.

Howard Fillit, MD
Executive Director
OUR MISSION

The Alzheimer’s Drug Discovery Foundation (ADDF) is the only non-profit organization whose sole mission is to accelerate the discovery and development of drugs to prevent, treat, and cure Alzheimer’s disease, related dementias, and cognitive aging.

We provide funding to scientists conducting promising Alzheimer’s drug research, primarily at academic institutions and biotechnology companies. In addition, the Foundation develops innovative scientific programs and conferences to bring together experts to address critical challenges in Alzheimer’s drug discovery.

OUR APPROACH

The ADDF uses a venture philanthropy model to bridge the gap in funding between basic research and later-stage development of Alzheimer’s therapies. Any return on investment is applied to new research projects.

As an unbiased philanthropic foundation, we do not invest in any single scientific method, institution, approach, or solution. We support a wide range of the most promising and novel Alzheimer’s drug research projects anywhere in the world. We also seek to develop a network of partnerships that will ultimately speed the development of effective, disease-modifying drugs for people with Alzheimer’s disease.

Under the leadership of our scientific staff, the ADDF maintains an external Scientific Review Board and a Business Advisory Board composed of experts in Alzheimer’s research and drug development. These external advisors are international leaders in identifying and evaluating research areas and projects that are worthy of ADDF support. In collaboration with the ADDF’s scientific staff, these external advisors review each grant application, help to refine proposed research ideas, assist with strategic management, and monitor the progress of each program. This approach ensures that each of the projects we support reaches its full potential.
First Annual Scientific Strategy Planning Committee Convened in 2010

In September, the ADDF convened its First Annual Scientific Strategic Planning Committee meeting in conjunction with our fall international conference. The committee is composed of eight scientists with expertise in Alzheimer’s disease and cognitive aging: Carol Colton, PhD, Duke University; Jeff Cummings, PhD, Lou Ruvo Center for Brain Health; Allan Green, MD, PhD, JD; Eli Michaelis, MD, PhD, University of Kansas; Lorenzo Refolo, PhD, National Institute on Aging; Linda Van Eldik, PhD, University of Kentucky; Molly Wagster, PhD, National Institute on Aging; and Michael Wolfe, PhD, Harvard Medical School and Brigham & Women’s Hospital.

This committee will help to guide the Foundation toward making the most effective use of our resources. Together with the ADDF’s Executive Director, Howard Fillit, MD, and Diana Shineman, PhD, Assistant Director for Scientific Affairs, the committee established our financing priorities for 2011:

The ADDF Research Funding Priorities
The ADDF will provide grants to academic laboratories and small biotechnology companies engaged in research to advance the discovery and development of novel therapeutics and diagnostic tools for Alzheimer’s disease, related dementias, and cognitive aging. The ADDF will select under-resourced projects that offer novel approaches to diagnosing, preventing, and treating Alzheimer’s disease. These novel approaches include developing drugs to prevent the loss of brain cells, improve cellular metabolism, and prevent blood vessel damage in the brain; identifying substances that can accurately diagnose Alzheimer’s and its progression; and developing drugs to attack the buildup of tau proteins in the brain.

PROFILES OF PROGRESS

In 2010, the ADDF continued to invest in three critical areas: biomarkers to aid in diagnosing Alzheimer’s disease; the discovery of novel Alzheimer’s drugs in academia; and supporting innovative Alzheimer’s research in biotechnology companies. We strongly believe that focusing
on these areas will lead to the identification and development of more effective therapies for Alzheimer’s disease. Each of these programs saw significant progress during the past year.

**EARLY DETECTION: BIOMARKER-BASED DIAGNOSTICS DEVELOPMENT PROGRAM**

Last year, the ADDF provided $1.1 million to researchers who are evaluating Alzheimer’s disease biomarkers – measurable substances, processes, and biological characteristics that indicate the presence or progression of the disease. Having a reliable biomarker is critical to developing accurate diagnostic tools that are capable of detecting Alzheimer’s in the early stages of the disease, when treatment may be most effective. Biomarkers may also be used to monitor disease progression and to measure the effectiveness of new drug candidates.

**Avid Radiopharmaceuticals, Inc.**

From 2000 to 2003, the ADDF granted $350,000 to researchers at the University of Pennsylvania to develop novel agents that bind to the protein beta-amyloid, a biomarker for Alzheimer’s disease that forms telltale plaques in the brain as the disease progresses. Agents that bind to this protein could be developed into an imaging test to diagnose Alzheimer’s disease in living patients and evaluate the effectiveness of new Alzheimer’s drugs. Previously, these plaques could only be detected through autopsy. In 2004, this successful ADDF-funded research program was spun out into a small biotechnology company, Avid Radiopharmaceuticals, to develop a novel molecular imaging agent, Florbetapir. Used with PET imaging technology, Florbetapir has the ability to identify the presence of beta-amyloid plaque deposits in the brains of living people. Beta-amyloid plaque is a defining pathology of Alzheimer's disease. Florbetapir is currently under review by the FDA. If approved, the Florbetapir PET scan will be the first diagnostic test for Alzheimer’s and will enable earlier intervention and improved diagnosis accuracy.

**The Alzheimer’s Disease Neuroimaging Initiative (ADNI)**

In 2004, the ADDF joined forces with the pharmaceutical industry, the National Institutes of Health, academic scientists, and the Alzheimer’s Association to launch a landmark study called the ADNI. The ADNI is an ongoing research initiative to evaluate and validate biomarkers for Alzheimer’s disease. One of the most important studies in
its field, ADNI has set the standard for the use of biomarkers in diagnosing Alzheimer’s disease and accelerating the development of drugs to treat it. The first study from this initiative validated the use of biomarkers that directly or indirectly measure Alzheimer’s progression, and may be used to predict cognitive decline or dementia in patients who are participating in clinical trials.

With continued support from the ADDF and other organizations, the ADNI will begin the second phase of its study in late 2011. This research will focus on evaluating Alzheimer’s biomarkers in a wider range of patients, including those in the earliest stages of Alzheimer’s disease and those with advanced dementia. Information from this study may help researchers refine the use of biomarkers to predict disease progression and patient outcomes in clinical trials. To learn more, visit www.adni-info.org.

**Drug Discovery Program**

In 2010, the ADDF granted $3.3 million to researchers engaged in Alzheimer’s drug discovery, indentifying compounds that may block or slow down the biological processes that cause Alzheimer’s disease and other dementias. ADDF-funded drug discovery projects are currently evaluating 15 different disease targets, each of which plays a role in the onset of dementia.

**Carmela R. Abraham, PhD, Boston University School of Medicine**

Klotho is an anti-aging protein that is named for the Greek goddess of fate who spins the thread of life. Studies have shown that mice with abnormally high levels of the protein are resistant to oxidative stress (an effect of aging) and live longer. In contrast, mice that lack Klotho show human-like signs of aging – such as hair loss, osteoporosis, and cognitive decline – and die prematurely. Abraham and her team found that levels of Klotho in the brain decline with age. Her research team is working to develop compounds that will increase Klotho levels and may counteract or delay the onset of many of the biological processes associated with aging, including cognitive decline and dementia.

**Biotechnology Program**

Fifty percent of our funding ($3.25 million) was awarded to biotechnology companies that are developing novel Alzheimer’s drugs. Smaller and much more focused than traditional pharmaceutical
companies, biotechnology companies often take a highly innovative approach to addressing unmet medical needs.

**AgeneBio Inc.**

AgeneBio Inc. is developing new therapies for mild cognitive impairment, a condition that often precedes Alzheimer’s disease. Evidence suggests that overactivity in a region of the brain involved in memory function may cause memory impairment in patients with mild cognitive impairment. Researchers at the company have identified a novel compound that reduces this overstimulation. ADDF funds will help to advance the preclinical development of therapies to counteract early, age-related cognitive impairment, when memory function could be rescued. Specifically, our grant will help the company to develop a medicinal chemistry program and a portfolio of compounds for clinical development.

**FOCUS ON ALZHEIMER’S CLINICAL TRIALS**

While over 300 potential treatments for Alzheimer’s disease have been shown to have some positive effect when tested in animals, drugs need to be tested in humans. The cost of human clinical trials – the gold standard for evaluating the safety and efficacy of a drug – is a barrier to developing many promising new Alzheimer’s therapies.

To address this problem, the ADDF launched its Program to Accelerate Clinical Trials (PACT). PACT will fund innovative new drug candidates that have shown potential in preclinical studies. Funding from PACT will give researchers the chance to generate the proof-of-concept clinical data that is needed to attract further and larger investment in later stage human clinical trials.

In 2010, the ADDF selected three early-stage clinical trials to receive PACT funding:

- **Metabolic Solutions Development Company**, Kalamazoo, MI, will conduct a Phase II clinical trial of its novel drug, Mitoglitazone, which binds to mitochondria in the brain. This approach may help brain cells resist the effects of aging, which could, in turn, improve memory. Preclinical studies suggested that the drug may also slow down the buildup of beta-amyloid plaques that are associated with Alzheimer's disease.
• Prana Biotechnology Ltd., Melbourne, Australia will conduct a Phase II clinical trial to evaluate the effectiveness of its novel therapy, PBT2, which aims to protect nerve cells from damage caused by beta-amyloid and oxidative stress. With the ADDF funding, the company will incorporate the use of PET imaging to measure the drug’s effectiveness.

• James Bennett, MD, PhD, of Virginia Commonwealth University, Richmond, VA, will continue developing a novel compound that helps to protect brain cells from oxidative stress in people with early-stage Alzheimer’s disease. With funding from the ADDF, Dr. Bennett will conduct additional safety studies and will include brain imaging to help evaluate the drug’s effectiveness.

PARTNERING FOR SUCCESS

The ADDF has an excellent track record of forging partnerships that strengthen our ability to achieve our programmatic goals.

To date, the ADDF has established partnerships with several of the most influential organizations in Alzheimer’s drug research, including the National Institute on Aging, Pfizer Inc., Elan Pharmaceuticals, the Aetna Foundation, the New York Stem Cell Foundation, the Lewy Body Dementia Association, and numerous private foundations.

The ADDF continues to establish partnerships that leverage resources in exciting new ways. In 2010, we were pleased to announce two partnerships:

Charles River Laboratories International, Inc./Cerebricon Ltd.
The ADDF collaborated with Charles River/Cerebricon to develop guidelines that identify best practices in the use of preclinical animal models of Alzheimer’s disease. These guidelines also aim to standardize the reporting of preclinical data, making it easier to evaluate and study outcomes and select the most promising preclinical compounds for human clinical development. An overview of the guidelines was released
in the fall of 2010. We expect to publish the full guidelines in a peer-reviewed scientific journal in 2011.

**Association for Frontotemporal Degeneration (AFTD)**

Up to 20% of all dementias are caused by frontotemporal dementia (FTD), a diverse group of disorders that initially affect the temporal and frontal lobes of the brain. Atrophy in these regions of the brain leads to disturbing symptoms such as changes in personality, behavior, and language. Previous research has shown that several different processes lead to this diverse group of disorders. In 2010, the ADDF and AFTD renewed their partnership to focus on discovering biomarkers to identify different types of FTD and guide the development of targeted therapies for the disease.

**CONFERENCES**

Scientific conferences promote the exchange of ideas, the sharing of research results, and the formation of strategic alliances to further drug development goals. In 2010, the ADDF held four scientific conferences, alone and in collaboration with other scientific institutions, to educate established scientists worldwide and the next generation of scientific leaders about the latest developments and challenges in Alzheimer’s disease research and drug development.

**4th Conference on Drug Discovery for Neurodegeneration**

*February 1-2 • Houston, TX*

**Collaboration with the National Institutes of Health**

More than 140 scientists from academic institutions, pharmaceutical and biotechnology companies, and government agencies from around the world participated in a comprehensive, two-day course on drug discovery for neurodegenerative diseases. The primary focus of the conference was to educate scientists about the challenges of translating basic research into the development of novel therapies for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. An online
tutorial on drug discovery, based on the conference proceedings, will be made freely available worldwide in 2011 to scientists who are interested in learning about the field.

**MITOCHONDRIAL FUNCTION AS A THERAPEUTIC TARGET FOR ALZHEIMER’S DISEASE**  
**May 18 ● New York, NY**  
**In partnership with the New York Academy of Sciences**  
This one-day symposium, attended by more than 200 scientists, presented current research on the importance of mitochondria – the energy hub of the cell – in maintaining the health of nerve cells. Discussions focused on the potential to translate basic research on mitochondrial dysfunction into novel therapies for age-related neurodegenerative diseases such as Alzheimer’s.

**11TH INTERNATIONAL CONFERENCE ON ALZHEIMER’S DRUG DISCOVERY**  
**September 27-28 ● Jersey City, NJ**  
More than 150 scientists attended this conference to learn about global efforts to find a cure for Alzheimer’s disease and related dementias. ADDF-supported researchers and Alzheimer’s experts presented their current research findings. A full meeting report will be published in the peer-reviewed journal, *Alzheimer’s Research & Therapy*.

**FEEDING THE PIPELINE: NOVEL TARGETS FOR ALZHEIMER’S DISEASE**  
**November 3 ● Toulouse, France**  
Nearly 250 scientists and industry experts participated in the ADDF’s first European symposium. Eight speakers from European biotechnology companies gave presentations on their efforts to identify novel compounds for Alzheimer’s disease across numerous disease targets.

**FUNDRAISING INITIATIVES AND EVENTS**
Thanks to our generous donors, the ADDF has granted more than $45 million to fund over 325 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 17 countries since its inception in 1998. In 2010, the ADDF hosted two major fundraising events to raise awareness about Alzheimer’s disease and attract additional support for early-stage drug discovery and development:
**FOURTH ANNUAL CONNOISSEUR’S DINNER: TO LIVE IS TO THINK**  
April 29 • Sotheby’s New York, NY  
Co-Chairs: Leonard A. Lauder and Nancy Corzine

The ADDF’s *Fourth Annual Connoisseur’s Dinner* raised $1.2 million for Alzheimer’s drug research, up more than 70% from 2009. Held at Sotheby’s New York, this elegant gathering was attended by 230 guests and featured extraordinary art, fine food, and exquisite wines. Jamie Niven, Chairman of Sotheby’s, North and South America, conducted a “Fund A Scientist” auction, which raised $301,550. The proceeds were awarded to Sidney Strickland, PhD, of the Rockefeller University, who is working to block amyloid-induced damage to blood vessels, and to Signum Biosciences, a biotechnology company with a novel approach to preventing the buildup of tau protein “tangles” in Alzheimer’s patients.

**HOPE ON THE HORIZON: NEW DRUGS FOR ALZHEIMER’S DISEASE**  
September 22 • The Pierre Hotel, New York, NY  
Executive Chairs: Leonard A. Lauder, Nancy and Mel Goodes, and Lynn Forester de Rothschild

The ADDF held its inaugural Fall Luncheon and Symposium in 2010 to increase awareness about the Foundation and Alzheimer’s disease. More than 260 guests attended the event, which generated over $630,000 for Alzheimer’s drug research. Highlights included Charlie Rose’s interview of Lars Ekman, MD, PhD, a world-renowned expert on pharmaceutical research and development; powerful remarks from Joan Sutton Straus, author and journalist; and keynote speaker Mel Goodes, former Chairman and CEO of Warner-Lambert, who has Alzheimer’s disease.

The event included an educational presentation given by the Foundation’s Executive Director, Howard Fillit, MD, entitled “Progress in Alzheimer’s Drug Discovery.” A webcast of the presentation is available at: www.alzdiscovery.org/index.php/progress.
HELP SUPPORT ALZHEIMER’S RESEARCH

An estimated 5.5 million Americans suffer from Alzheimer’s disease and related dementias. Every 70 seconds, someone is diagnosed with Alzheimer’s disease. Currently, this neurodegenerative disease is the fifth-leading cause of death in the United States. The need for drugs to prevent, treat, and cure Alzheimer’s disease has never been greater. The Alzheimer’s Drug Discovery Foundation is committed to conquering this devastating disease.

Beginning in 2011, all of the Foundation’s administrative and operational costs will be covered by a private foundation, the Institute for the Study of Aging, which was founded by the Lauder Family. As a result, 100% of funds raised by the ADDF will be used to support scientific research to develop new treatments for Alzheimer’s disease.

The ADDF will keep working to promote the innovative scientific thinking that is needed to develop novel therapies for this devastating disease. But we cannot do it alone. Please give generously today at www.alzdiscovery.org.
**2010 GRANTS**

**ACADEMIC PROGRAMS**

**Pancham Bakshi, PhD**  
Roskamp Institute  
Sarasota, Florida  
CXCR2-Antagonism: Novel Therapeutic Approach for Alzheimer's Disease  
Award: $126,000

**Carlo Ballatore, PhD**  
University Of Pennsylvania  
Philadelphia, Pennsylvania  
Optimization of Aminothienopyridazine Inhibitors of Tau Aggregation  
Award: $110,000

**James Bennett, MD, PhD**  
Virginia Commonwealth University  
Richmond, Virginia  
Safety/Tolerability and Effects on Cognitive Impairment, Impaired Cerebral Cortical Metabolism and Oxidative Stress of R (+) Pramipexole Administered To Subjects with Early Alzheimer's Disease  
Award: $501,200

**Karl-Heinz Braunewell, PhD**  
Southern Research Institute  
Birmingham, Alabama  
Drug Discovery for the Neuronal Calcium Sensor (NCS) Protein VILIP-1 as Possible Target for Cognitive Impairment in CNS Disorders  
Award: $76,000

**Michelle Carlson, PhD**  
Johns Hopkins Bloomberg School of Public Health  
Baltimore, Maryland  
Effects of a Social Health Promotion Program on Neurocognitive Function: Experience Corps  
Award: $152,000

**Li Gan, PhD**  
The J. David Gladstone Institutes  
San Francisco, California  
Development of Allosteric Activators of Cathepsin B to Treat Alzheimer's Disease  
Award: $125,000
Lawrence Honig, MD, PhD
Columbia University
New York, New York
Combined CSF Biomarkers and GBA Genotype for Diagnosis of LBD
Award: $125,000

Varghese John, PhD
Buck Institute for Research on Aging
Novato, California
Identification of Inhibitors for the C-Terminal D664 Cleavage of APP as Potential Therapeutic Agents for Alzheimer's Disease
Award: $115,000

Rakez Kayed, PhD
University Of Texas Medical Branch
Galveston, Texas
Tau Oligomers for Treatment of Alzheimer’s Disease
Award: $82,700

Iliya M. Lefterov, MD, PhD
University Of Pittsburgh
Pittsburgh, Pennsylvania
Antiamyloidogenic and Anti-Inflammatory Effects of Proton Pump Inhibitors in AD Model Mice
Award: $75,800

Paul Lombroso, MD
Yale University Medical School
New Haven, Connecticut
Screening For Inhibitors of STEP
Award: $142,300

Lennart Mucke, MD
The J. David Gladstone Institutes
San Francisco, California
Genome Wide RNAi Screen to Identify Inhibitors of Tau Expression
Award: $177,700

Roger Olsson, PhD
Lund University
Lund, Sweden
Development of SARMs as Alzheimer’s Disease-Modifying Drugs
Award: $162,150
Pavel Petukhov, PhD  
University of Illinois at Chicago  
Chicago, Illinois  
Mapping the Binding Site of HDAC 2 for the Design of Novel HDAC Inhibitors Lacking Zinc Binding Group  
Award: $142,100

Christopher Rowe, MD  
Austin Hospital Medical Research Foundation  
Melbourne, Australia  
Australian Imaging, Biomarkers and Lifestyle Study Of Ageing (AIBL)  
Award: $115,000

Judith Siuciak, PhD  
Foundation for the National Institutes of Health  
Bethesda, Maryland  
Use of Targeted Multiplex Proteomic Strategies to Identify Cerebral Spinal Fluid-Based Biomarkers in Alzheimer’s Disease  
Award: $100,000

Yaakov Stern, PhD  
Columbia University  
New York, New York  
Neural Basis for the Combined Effects of Cognitive Stimulation and Aerobic Exercise on Cognition in Aging  
Award: $70,000

Sidney Strickland, PhD  
The Rockefeller University  
New York, New York  
Interaction between Abeta and Fibrinogen: A New Therapeutic Target for Alzheimer’s Disease  
Award: $150,000

Grace Stutzmann, PhD  
Rosalind Franklin University of Medicine and Science  
North Chicago, Illinois  
Targeting Neuronal Calcium Dysregulation to Halt AD Pathogenesis  
Award: $100,000

Michael W. Weiner, MD  
Foundation for the National Institutes of Health  
San Francisco, California  
Alzheimer’s Disease Neuroimaging Initiative (ADNI)  
Award: $50,000
Michael S. Wolfe, PhD  
Brigham & Women’s Hospital  
Boston, Massachusetts  
Targeting the Tau Message for Dementia  
Award: $125,000

BIOTECHNOLOGY PROGRAMS

Dianne Angus  
Prana Biotechnology Ltd.  
Parkville, Australia  
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of PBT2 (Once Daily For 52 Weeks) On Abeta Deposition in the Brain of Patients with Alzheimer's Disease  
Award: $700,000

Steven P. Braithwaite, PhD  
Signum Biosciences, Inc.  
Monmouth Junction, New Jersey  
Phosphoprotein Phosphatase 2A (PP2A): A Novel Therapeutic Target for Alzheimer's Disease: For Clinical Development of SIG1012  
Award: $150,000

Susan Catalano, PhD  
Cognition Therapeutics, Inc.  
Pittsburgh, Pennsylvania  
Behavioral Efficacy Testing Of Anti-Abeta 42 Oligomer Small Molecules  
Award: $228,668

Jerry Colca, PhD  
Metabolic Solutions Development Company  
Kalamazoo, Michigan  
Evaluation of MSDC-0160 in Subjects with Mild Alzheimer’s Disease  
Award: $773,100

Stephen Curry, MD, PhD  
Adispell, Inc.  
Rochester, New York  
Combining Enhanced Neurotransmission and Inhibition of Beta-Amyloid Toxicity in Treating Cognitive Disorders in Alzheimer’s Disease  
Award: $170,750

Michela Gallagher, PhD  
Agenebio Inc.  
Baltimore, Maryland  
Selective GABA A5 Ligands for Cognitive Enhancement in Patients with Mild Cognitive Impairment  
Award: $244,500
Greg Hook, JD, PhD  
American Life Science Pharmaceuticals, Inc.  
San Diego, California  
GMP Production of E64d  
Award: $248,000

Tamara Maes, PhD  
Oryzon Genomics, S.A.  
Barcelona, Spain  
First in Class Modifying Disease Drugs for Alzheimer's Disease  
Award: $300,000

Allen Reitz, PhD  
ALS Biopharma, LLC  
Doylestown, Pennsylvania  
Heat Shock Protein Inducers for the Treatment of Alzheimer's Disease  
Award: $195,000

Tim West, PhD  
C2N Diagnostics  
Saint Louis, Missouri  
Preclinical Development of Plasma-Based AD Diagnostic Test Using a Combination of Antibody Administration and Stable Isotope Labeling Kinetics  
Award: $247,482

ADDF/AFTD* PARTNERSHIP GRANTS

William Hu, MD, PhD  
Emory University School of Medicine  
Atlanta, Georgia  
CSF Biomarkers of FTLD-TDP and FTLD-Tau – A Multi-Center Study  
Award: $100,000

Allen Roses, MD  
Duke University  
Durham, North Carolina  
Fine-Mapping and Characterization of Genetic Biomarkers That Facilitate the Acceleration of Drug Discovery for Frontotemporal Dementias  
Award: $125,000

Marcel M. Verbeek, PhD, MSc  
Stichting Katholieke Universiteit  
Nijmegen, Netherlands  
TDP-43 and Tau as Cerebrospinal Fluid Biomarkers to Discriminate Frontotemporal Dementia Subtypes  
Award: $100,000
Victor Villemagne, MD
Austin Health
Heidelberg, Australia
[18F]-THK523, A Novel In Vivo Tau Imaging Agent
Award: $135,000

*The Association for Frontotemporal Dementias

CONFERENCES

Israel Hanin
Kenes International
Geneva, Switzerland
The 10th International Congress on Alzheimer’s & Parkinson’s Diseases
Award: $10,000

Andrew Robertson, PhD
Keystone Symposia on Molecular and Cellular Biology
Silverthorne, Colorado
Neurodegenerative Diseases: The Molecular and Cellular Basis for Neurodegeneration
Award: $2,500
Thanks to the generosity of the following donors, the ADDF raised approximately $8.6 million in 2010 – a 56% increase over funds raised in 2009. Your support enabled us to advance our mission of accelerating drug discovery for Alzheimer’s disease, related dementias and cognitive aging.

Over $1,000,000

Mr. and Mrs. Mel Goodes  
The Leonard and Evelyn Lauder Foundation

$100,000 to $999,999

Aetna Foundation  
Anonymous  
The Association for Frontotemporal Degeneration  
Sir Evelyn and Lady Lynn de Rothschild  
The Estée Lauder Companies Inc.  
Mr. and Mrs. Leonard Lauder  
Mr. and Mrs. Randal Sandler

$50,000 to $99,999

Charles River CHARTER Program  
Ms. Nancy Corzine  
Mr. and Mrs. Marc Lefkowitz  
National Institutes of Health  
Dr. Nathan E. Saint-Amand

$25,000 to $49,999

Ms. Carol Seabrook Boulanger  
Mr. and Mrs. Louis Caceres  
Condé Nast Publications  
Mr. and Mrs. Steven Crown  
Datio Family Foundation, Inc.  
Ernst & Young, LLP  
Flexjet  
Anne and Kenneth Griffin in memory of Ms. Genevieve Gratz  
Le Papillon Ltd./Watson C. Warriner, Jr.  
Merck Research Laboratories  
The David A. and Mildred H. Morse Charitable Trust  
Pfizer Inc.  
Sotheby’s  
Mrs. Joan Sutton Straus  
Mr. and Mrs. Donald Tober

$10,000 to $24,999

Mr. Dennis Basso and Mr. Michael Cominotto  
Robert and Renée Belfer Family Foundation  
Mr. and Mrs. Scott Black  
Bloomberg  
Mr. and Mrs. Arthur Carter  
Valerie-Charles Diker Fund, Inc.  
Elan Corporation, plc.  
Mrs. Nancy Epstein, Artistic Tile  
Teauman and Grace Fuite Foundation  
Elias Gelman Family Foundation  
Albert Glickman Family Foundation  
INOAC Packaging Group, Inc.  
Mr. and Mrs. Michael Katzke  
Mr. and Mrs. Howard Kessler  
Mrs. Bonnie Englebardt Lautenberg  
Mr. and Mrs. William P. Mahoney  
McKinsey & Company, Inc.  
Ms. Jennifer Miller and Mr. Mark Ehret  
Marc and Shelah Moller Foundation  
Samuel I. Newhouse Foundation, Inc.  
Mr. Thomas C. Quick  
Ms. Patricia Quick  
Mr. and Mrs. Douglas Rosenberg  
Mr. and Mrs. Howard J. Rubenstein
Mrs. Jeanette Sarkisian and
Dr. Paul A. Wagner
Mr. and Mrs. George W. Schiele
Seabrook Foundation
Tishman Speyer Properties, LP
U.S. Trust, Bank of America
Private Wealth Management
Mr. and Mrs. Sadek Wahba
Mr. and Mrs. Michael Weisman
Mr. and Mrs. Keith Wellin
Mr. and Mrs. Galen Weston
Lois and Andrew Zaro
Family Charitable Trust

$5,000 to $9,999

Mr. and Mrs. Frederick R. Adler
Allon Therapeutics Inc.
Alzheimer’s Foundation of America
Mr. and Mrs. Steven Ames
Mr. and Mrs. David M. Baldwin
Mr. and Mrs. Ron Baron/Baron Capital Foundation
Mr. Howard B. Bernick
Beyond Batten Disease Foundation
Biogen Idec
Charles Evans Foundation
Mr. and Mrs. Gary Conrad
Guy and Virginia Dietrich, The Eastwell Trust
Mr. and Mrs. Todd Eagle
The Edgerley Family Foundation
Ehrenkranz Family Foundation
Mr. and Mrs. Mitchell Eichen
Mr. and Mrs. Roger Einiger
The Engelberg Foundation
ExonHit Therapeutics, Inc.
William H. G. FitzGerald Family Foundation
Michael J. Fox Foundation for Parkinson’s Research
Mr. Richard I. Furman
Mr. and Mrs. David Goodes
Mr. and Mrs. William L. Hanley Jr.
Dr. Michelle Hobart and Mr. Justin Peyser
Mr. and Mrs. Richard Jaffe
Kekst and Company Incorporated

Mr. and Mrs. John R. Kennedy
The Larini Family Foundation
Mr. William P. Lauder
Mr. and Mrs. Larry Leeds
Mr. and Mrs. Harry Lis
Mr. and Mrs. Alan J. Maguire
Mrs. Jack C. Massey/Jack C. Massey Foundation
Ms. Carlyn S. McCaffrey
Mr. and Mrs. James N. Mills
Mr. Charles Moffett
Mr. N. Norman Muller
Mr. Jiro Murase
Mutual of Omaha Insurance Company
Mr. and Mrs. Richard Parsons
Mr. and Mrs. Timothy Pasik
Mr. and Mrs. Robert Prince
Mr. and Mrs. William Rayner
Mr. and Mrs. Joseph Riccardo
Robins, Kaplan, Miller & Ciresi LLP
Mr. and Mrs. Wilbur L. Ross, Jr.
Ms. Kerri Scharlin and Mr. Peter Klosowicz
Richard, Ann, John and James Solomon Family Foundation
The Sheldon H. Solow Foundation
Mr. and Mrs. Paul Stelzer
Ms. Deborah A. Terhune
The Rockefeller University
UBS Private Wealth
Vanguard Charitable Endowment Program
The Vradenburg Foundation
Ms. Giselle F. Wagner and Mr. Paul Myerson
Dr. Janet Werkmeister and Dr. Howard Fillit
Mr. and Mrs. Eric Zinterhofer

$1,000 to $4,999

Abbott Laboratories, Inc.
A G Foundation
Dr. Lisa Airan
AnaSpec, Eurogentec Group
Aprelica Inc.
Mr. and Mrs. Manucher Azmudeh
Mr. and Mrs. Martin Balsam
Mr. and Mrs. Sid R. Bass
Mr. and Mrs. Philip J. Bazelides
Mr. and Mrs. Joe Bachelder
Ms. Karen H. Bechtel
Geoffrey Beene Foundation
  Alzheimer's Initiative
Mr. Leonard J. Bencivenga
Mr. Kenneth Bernardo
Mr. and Mrs. Daniel S. Bernstein
Mr. Raphael Bernstein
Ms. Terre Blair and Mr. Marvin Hamlisch
Nancy and Robert S. Blank Foundation
Mr. Thomas R. Boehlke
Mr. and Mrs. Daniel Brodsky
Ms. Bari Burman
Cambridge Cognition, Ltd.
Mr. and Mrs. Michael Carr
Certus International Inc.
ChanTest Corporation
Ms. Lois Chiles and Mr. Richard Gilder
Mr. Marshall P. Cloyd
Mr. Michael T. Cohen
Mr. and Mrs. Charles Collat, Sr.
Colliers International
Ms. Laura Corwin and Mr. Portis Hicks
Ms. Carol S. Desipio
Ms. Beth Rudin DeWoody
Ms. Amy DiGeso and Mr. Paul Rakowski
Ms. Angela Smith Domzal
The Honorable and Mrs. Edward E. Elson
Mrs. Mica Ertegün
Mr. and Mrs. Melvyn J. Estrin
Ms. Bonnie Pfeifer Evans
Mr. and Mrs. Robin L. Farkas
Mr. and Mrs. David C. Farrell
Mr. and Mrs. Niall M. Ferguson
Ms. Arti V. Finn and
  Mr. Christopher Grewe
Mrs. Jennifer Fischer
Mrs. Harriet Foster
Fross, Zelnick, Lehrman & Zissu, PC
Mrs. Veronique Gabai-Pinsky and
  Mr. Joel Pinsky
Mr. Larry Gagosian
Ms. Karen Galland
The Honorable Richard N. Gardner
GE Healthcare
Senator Roy M. Goodman
Mr. and Mrs. James Gordon,
  The Edgewater Funds
Dr. and Mrs. Allan Green
Ms. Sylvia Greenberg
Ms. Cecilia Greene
Ms. Glenda Greenwald
Mr. and Mrs. Phil Gross
Guardsmark
Mr. Bruce D. Haims
Mr. and Mrs. Edward Hansen
Mr. Wills Hapworth
Mr. James L. Haskel
Mrs. Bobba Paul Hauserman
Mr. and Mrs. David Heller
Mr. and Mrs. Lawrence Herbert
Mr. and Mrs. Roger Hertog
Ms. Marlene Hess and Mr. James D. Zirin
Mr. James Hogan
Ms. Beth A. Hollister
Hurtok & Daroff Co.
Mr. Mark Hutchinson
Imperatum Holdings, Inc.
International Discovery Services &
  Consulting, LLC
J. Howard Johnson and Brenda L. Johnson
  Family Foundation
JRS Dryfoos Charitable Lead Trust
JSW Life Sciences GmbH
Mr. and Mrs. Harry P. Kamen
Ms. Riki Kane and Mr. Robert Larimer
Mr. Fred Kaplan
Mr. and Mrs. George Kaufman
The Richard W. Keetly Foundation
Mr. and Mrs. William Kenyon
Ms. Karyn A. Khoury
Mr. and Mrs. David Klein
Mr. and Mrs. Kevah Konner
Ms. Stephanie Krieger
The H. Frederick Krimendahl II Foundation
Mr. and Mrs. Peter Krulwitch
Ms. Joan Krupskas and Mr. Ted Barbour
Ms. Elizabeth S. Kujawski
Ms. Mary Lamothe and Mr. Nathan Tinker
Mrs. Emily Fisher Landau
Mr. and Mrs. Gary Lauder
Mr. and Mrs. Brian C. Lawlor
Ms. Alexandra Lebenthal and
Mr. Jeremy Diamond
Mr. Michael Lefenfeld
Mr. and Mrs. Morvin Leibowitz
Mr. Kevin Leifer
Mr. and Mrs. Noel Levine
Mr. and Mrs. Irvin Levy
Mr. Peter B. Lichtenthal
J.A. Lindeman & Co. PLLC
Mr. and Mrs. Samuel H. Lindenbaum
The Litwin Foundation, Inc.
Mr. Mark Locks
Mr. Daniel S. Loeb
The Thomas H. and Jarman F. Lowder
Foundation
Mr. and Mrs. John D. Lowenberg, Sr.
Ms. Lindsay Lullman and Mr. José Mestre
Dr. and Mrs. Jerry Lynn
Mr. and Mrs. Mitchell Lynn
Ms. Jennifer Lynn
The Honorable and Mrs. Earle I. Mack
Dr. and Mrs. Robert Magoon
Mr. and Mrs. Vincent Mai
Mr. and Mrs. Peter Malkin
Mr. Elliott Maltzman
Mr. John P. Mascotte
Mr. and Mrs. Arthur D. Mason
Mr. and Mrs. Jonathan P. May
The William E. Mayer Charitable
Foundation
Mr. and Mrs. Robert McCabe
Mr. and Mrs. Thomas McGrath
Megagen USA Inc.
Ms. Dina Merrill and Mr. Ted Hartley
Edward and Sandra Meyer Foundation
Mr. and Mrs. Sam Michaels
Mr. and Mrs. Donald K. Miller
Mr. and Mrs. David Mitchell
The Mnuchin Foundation
Ms. Judith Mogul and Mr. Daniel J. Kramer
Mr. and Mrs. Edward Moran
Mr. and Mrs. Lucian Morrison
Newmark & Company Real Estate Inc.
Mrs. William A. Nitze

The Nola Foundation
Ms. Deborah Norville and Mr. Karl Wellner
Mr. and Mrs. Moshe Orenbuch
Mr. and Mrs. Richard S. Pearman
Mr. and Mrs. John. J. Phelan, Jr.
Pillsbury Winthrop Shaw Pittman LLP
Mrs. Cynthia Hazen Shaw Pittman and Mr. Leon B.
Polsky
Mr. and Mrs. John Pomerantz
Mr. and Mrs. Stephen W. Porter
Ms. Elizabeth A. Poynor, MD
Preissman-Beriro Foundation
Mr. Craig A. Reynolds
The Ripple Foundation
Mr. Daniel Ritter
Ms. Molly Robb
Mrs. Sheila J. Robbins
Rockefeller Financial
Rolex Watch U.S.A.
Dr. and Mrs. Leon Root
Susan & Elihu Rose Foundation, Inc.
Benjamin M. Rosen Family Foundation
Mr. Joseph B. Rosenblatt
Mr. Keith Rosenbloom
Ms. Janet C. Ross
Jon & Susan Rotenstreich Foundation
Peter Thomas Roth Labs, LLC
Dr. and Mrs. Ronald M. Roth
Mr. and Mrs. William C. Rudin
The Russo Family Foundation
Mr. Kevin M. Ryan
Mr. and Mrs. Mortimer Sackler
Mr. and Mrs. Sal Salibello
Mr. and Mrs. Richard E. Salomon
Mr. and Mrs. Nathan Sandler
Dr. Deborah Sarnoff and Dr. Robert Gotkin
Mr. Robert Savell
The Schiff Foundation
Mr. Howard Schiffman
Mr. and Mrs. Mitchell Schrage
Ms. Pamela Seymon and Mr. Robert
Schumer
Mr. Adam Shapiro
William and Jacqueline Shaw Family
Foundation
Mr. and Mrs. Stephen Shepard
Mr. and Mrs. Stephen Shimshak
Ms. Alice Shure
Mr. and Mrs. Albert H. Small
Mr. and Mrs. Joseph E. Smith
Mrs. Anne Smthers
Mr. and Mrs. Peter Solomon
Mr. and Mrs. Richard Solomon
Mr. and Mrs. Gavin Solotar
Mr. Maurice Sonnenberg
Mr. and Mrs. Cary Stamp
Mr. and Mrs. Marc Sulam
Mr. Stephen Surgit
The Susan Stein Shiva Foundation
Susman Family Foundation
The A. Alfred Taubman Foundation
Mr. Ronald Temple
Ms. Andrea T. Travaglia
Ms. Amy G. Treitel
Ms. Alexandra Trower and Mr. Jon Lindsey
United Eway
Ms. Sahba Vaziri and Mr. Ali Reza
Mr. Robert J. Weber, Jr.
Mr. and Mrs. Ronald Weintraub
Dr. Arthur C. Weisenseel
Mr. W. Grant Williams
Ms. Linda Zambelli
Mr. Gary Zarr
Mr. Richard W. Ziegelasch
Mr. Mortimer B. Zuckerman

Ms. Jennifer Balbier
Ms. Rachel Balsam
Mr. and Mrs. David Baluarte
Ms. Eve Barron
Dr. and Mrs. Martin Becker
Bencivenga Ward & Company, CPA's P.C.
Ms. Jackie Bennett and Mr. Jeff Fishbein
Mr. and Mrs. Bob Bennett
Mr. Kenneth E. Bentsen
Ms. Joan L. Beranbaum
Mr. and Mrs. Bruce Berger
Judy and Howard Berkowitz Foundation
Mr. Allan J. Berman
Mr. and Mrs. Chris Beusman
Mr. John K. Binswanger
Mr. Neil Bisciello
Mr. and Mrs. Bernard Bloom
Ms. Judith Boies and Mr. Robert Christman
Ms. Meleena Bowers
Mr. and Ms. Richard S. Braddock
Bradford Family Foundation
Mr. Steven R. Bralove
Ms. Susan G. Brand and Mr. Robert Jones
Mr. and Mrs. Mitchell Brand
Ms. Rose Marie Bravo and
Mr. William Jackey
Bryant Family Foundation
Mr. and Mrs. Walter H. Buck
Ms. Mary K. Bush
Ms. Sharon Bush
Dr. Robert N. Butler
Ms. Frances Butler
Mr. Josh Cammaker
Mr. Jerome Cangelosi
Mr. Paul Canty
Caplan Family Foundation Trust
Cards for Causes
Carlson Wagonlit Travels
Mr. Jordan Carqueville
Ms. Rebecca Carvalho
Ms. Constance Cocroft
Ms. Adele Cohen
Dr. Edwin L. Cohen
Mr. and Mrs. Jerome Cohen
Ms. Nancy Collamer
Mr. Daniel Colón, Jr.
Ms. Meryl Comer
The Community Foundation for the National Capital Region
Mr. and Mrs. Bill Conner
Ms. Cindy Convery
Mr. and Mrs. Stephen Cornick
Mr. and Mrs. Marc Cornstein
Mr. and Mrs. William Cox
Ms. Kelly Culbertson
Ms. Laura Dalle Pazze
Ms. Mikki Davis
Ms. Danielle De Santis
Mrs. Debow and Mr. Soldavan
Mr. Eric DeCastro
Mr. Kevin Dieterich
Ms. Angela DiGennaro
Ms. Jacquelyn Dille
Ms. Melanie DiStante
Mr. Rajit Dosanjh
Mr. and Mrs. Rodman Drake
Ms. Beatrice DuPont
Mr. Josh Eisenman
Ms. Amina El Ayadi
Mr. Sergio Elejalde
Ms. Lisa Elliot
Elmwood Country Club
Ms. Elisabeth Evans
Mr. and Mrs. Norman Falkin
Mr. Timothy Farnsworth
Ms. Danielle Fassman
Ms. Joyce Feinberg Luchtenberg
Mr. Irving Feist
Mr. Peter Felo
Mr. and Mrs. Harry Fields
Ms. Rochelle Finkelstein
Ms. Valerie Fitch
Fontana Design Group
Mr. and Mrs. Michael E. Foster
Mr. and Mrs. Carl Fowler
Mr. James Franklin
Ms. Jennifer Franklin
Mr. Spencer Freedman
Mr. Jay W. Freedman
Mr. John Fressie
Fried, Frank, Harris, Shriver & Jacobson LLP
The Barry Friedberg and Charlotte Moss Foundation
Frontier Natural Products Co-op
Mr. and Mrs. John Fullam
Melissa T. Gagen
Ms. Maria T. Galeno
Ms. Jennifer Gambino
Ms. Veronica Garaycochea-Williams
Ms. Gloria Gardner
Ms. Andrea Gerich-Miller
Mr. David Gerson
Mr. and Mrs. Emile Ghattas
Mr. and Mrs. Michael Gibbons
Mr. and Mrs. Gerald Z. Gibian
Ms. Evelyn S. Gilman
Ms. Christina Giuca
Givebackamerica, LLC
Ms. Missy Godfrey and Mr. David Fitzpatrick
Mr. and Mrs. Robert Goldfarb
Mrs. Jill Goldman
Ms. Patricia Goldstein
Mr. and Mrs. Adam Goldstein
Ms. Lilia Goldstein
GoodSearch
Mr. Mark Gordon
Mr. and Mrs. Thomas M. Gorrie
Ms. Maria Gotsch
Mr. and Mrs. Joshua Gray
Ms. Jodi Greebel
Dr. Cynthia Green
Mr. Jeremy Greenberg
Mr. and Mrs. Troy Gregory
Ms. Martha Gross and Mr. Robert Tracy
Ms. Sanae Guerin
Mr. Matthew Gulker
Mr. and Mrs. Morton I. Hamburg
Ms. Helena Harnik
Mr. Chris Harris
Lady Mercia Harrison
Ms. Barbara Hawes
Ms. Pamela Heckel
Mr. Nicholas Hecker
Hewitt Pharmacy
Ms. Serena Hicks
Ms. Debbie Hillard
Stanley R. Miller Foundation
Ms. Lisa Min
Ms. Ali Mirsaidi
Mr. and Mrs. Richard Mishaan
Ms. Erin Moennich
Mr. and Mrs. Mike Monroe
Mr. and Mrs. Henry Morgenbesser
Mr. and Mrs. Lester S. Morse, Jr.
Mr. and Mrs. Charles H. Mott
Mr. Michael Muller
Mr. Curt Myers
Mr. John Myers
Mr. Thomas Nall
Mr. Vaibman Narayan
Dr. and Mrs. David T. Nash
Ms. Renee Nathanson
Ms. Judith E. Neisser
Mr. Joseph Nemia
Network for Good
Ms. Melissa Neumann and Mr. James Cric
NeuroStructural Research Labs, Inc.
New York City Partnership Foundation, Inc.
The New York Community Trust
Dr. and Mrs. Howard Newhouse
Novus Biologicals, LLC
Nucor Construction Corporation
Mr. and Mrs. Andrew J. Nussbaum
The Honorable Sandra Day O'Connor
Ms. Valerie O'Halloran
Ms. Allison Oppenheim
Ms. Margaret M. Owen
Dr. John Q. Owsley
Mr. Adam Ozmer
Mr. George Palmer
Mr. Thomas J. Parciak
Mr. and Mrs. Edward C. Parisi
Ms. Darlene Pasquill and Mr. Mike Hiller
Mr. and Mrs. Jerry P. Peppers
Dr. and Mrs. Leon Perahia
Peregrine Investment Holdings, LLC
Ms. Jenice Perez
Mr. and Mrs. Brian Perlman
Mr. Louis Perlman
Mr. Louis Pesale
Mr. and Mrs. Jeffrey Pettit
Pfizer Foundation Matching Gifts Program
PharmatrophiX, Inc.
Dr. and Mrs. Walter Pinsker
The Pittman Family Foundation
Mr. and Mrs. Philip L. Platt
Paul G. Podolsky
Mrs. Gina Pollock
Mr. and Mrs. Zachary R. Pomerantz
Ms. Deborah Pratt Dawson
Mrs. Andrea and Mr. Joel Press
The Price Family Foundation, Inc.
Mr. and Mrs. Tom Quinn
Dr. Irfan Qureshi
Mr. Jay Rabin
Ms. Linda Rabino
Mr. and Mrs. Risher Randall
Ms. Katie Reimer
Mr. Jerome Reinert
Mr. Chad D. Rencher
Mr. Scott Reynolds
Mr. and Mrs. Gary Richter
Ms. Catherine Riva
Mr. and Mrs. John E. Rorer
Mr. Eric Rosen
Ms. Jane Rosen
Mrs. Zita G. Rosenthal
Mr. and Mrs. John Ross
Ms. Joann Rossi
Mr. Anthony Rotondaro
Mr. Olivier Roux
Mr. Slava Rubin
Ms. Stacy Rubin
Mrs. Myrna Ruskin
Mr. and Mrs. Stephen R. Rusmisel
Mr. Peter Rust
Mr. Arthur Sachs
Mr. and Mrs. Richard Sandler
Mr. David Saunders
Mr. and Mrs. George S. Saunders, Jr.
Mr. Thomas Savino
Mr. and Mrs. Richard Sawczyn
Ms. Frances G. Scaife
Ms. Vera Scanlon
Ms. Gail Schargel and Mr. William Powell
Ms. Amy Scherick
Mr. and Mrs. Tony Schneider
Mrs. Pat Schoenfeld
Ms. Nancy Schueneman
Mrs. Barbara Schwartz
Ms. Joanna Schwartz
Ms. Stephanie Scott
Mr. and Mrs. James M. Seabrook
Mr. and Mrs. Doug Selin
Mr. and Mrs. Sandy Severino
Mr. Michael Shara
Mr. Neil C. Sharpton
Ms. Stephanie Shperd
Mr. and Mrs. James Shequine
Mr. Doug Shineman
Mr. and Mrs. Eric Shrubsole
Mr. Francois D. Sicart
Mr. and Mr. Warren Siegmond
Mr. William Silverman
Mr. Frank G. Sinatra
Mr. and Mrs. Joshua Slocum
Mr. and Mrs. Spencer Smul
Ms. Karen Snow
Mrs. Lisa Somar
Mrs. Constance Spahn
Ms. Jill Spalding
Ms. Debbie Spano
Ms. Robin L. Spear
Mr. Scott M. Spielberger
Dr. and Mrs. Robert Spira
Ms. Susan Spivak and Mr. Edward Rucker
SRI International
Ms. Alise Steinberg
The Laura Steinberg Tisch Foundation, Inc.
Norman C. Stone, Ph.D.
Mr. and Mrs. Trevor Sumner
Ms. Anne Suzuki
Ms. Mary B. Szalkowski
Ms. Lauri A. Szymanski
Ms. Rhonda Tannenbaum
The Honorable Kenneth D. Taylor and Dr. Patricia Taylor
Mrs. Michelle Taylor
Mr. Jigme Tethong
The Bank of New York Mellon Community Partnership
Mr. and Mrs. Roger Thomas
Mr. and Mrs. Michael Thoyer
Ms. Mary Tilt
Mr. and Mrs. Justin Tinsley
Ms. Catherine Todd
Mr. Ivo Tomulich
Town, LLC
Mr. and Mrs. Marvin Traub
Mrs. Joy Ubiña
Ms. Brooke Ugel
United Way of New York City
University of Kentucky
Ms. Chele Upton Chiavacci
Mr. Daniel van den Bergh
Ms. Alexis Varela
Mr. Andres Varon
Ms. Sherri Vassallo
Mr. Brian Wagner
Mrs. Cynthia Wagner
Ms. Alana Waisbrot
Mr. Dave R. Wall
Ms. Stefanie Wallach
Ms. Katherine Walley
Mr. and Mrs. Bryan Walley
Mr. and Mrs. Joe Walsmith
Mr. and Mrs. Robert Waxman
Ms. Limor Weizmann
Mr. and Mrs. David Westin
Ms. Carlie Willard
Ms. Diane B. Wilsey
Mr. and Mrs. Christian Wollny
Ms. Jennifer Wright
Mr. Paul Wright
Ms. Kylie Wright-Ford
Mr. Evan Yellin
Mr. James Yockey
Mr. William Young
Mr. Richard W. Ziegelasch
Ms. Pamela Zilly
Mr. and Mrs. Ken Ziman
Mr. and Mrs. Marc Zimman

Gifts In-Kind

Artistic Tile
Ben Gabbe Photography
Boston Celtics
Bumble and bumble
Canard Inc.
CHDI Foundation
Cipriani
Ms. Nancy Corzine
Mr. Peter de Savary, Vanderbilt Hall
Debevoise & Plimpton LLP
Delta Airlines
Design Cuisine
Donna Karan International
The Estée Lauder Companies Inc.
Fast Forward, LLC
Ferragamo
Four Seasons Hotel, New York
Fourth Wall Restaurants
HealthyChocolateNY.com
The Houston Museum of Natural Science
Italian Wine Merchants
Jennifer Lynn
Jennifer Miller Jewelry
JetBlue Airways
Judith Leiber
Mr. and Mrs. Paul Kanavos
Mr. and Mrs. Leonard A. Lauder
Le Cirque
Loews Miami Beach Hotel
Marc Jacobs
Martha Stewart Living Omnimedia
Meredith Vieira and Valley Crest Productions
Metrokane
Microsoft Corporation
Möet and Chandon
Mohegan Sun
Montblanc North America, LLC
Ms. Jennie Ng LoPresto
Ms. Phyllis Pittman
Quest Magazine
SARAR
Sidebar
Siegel and Gale
Sotheby’s
The Napa Valley Reserve
The Palm
The Plaza Hotel
The Ritz-Carlton, South Beach
The Ritz-Carlton, Westchester
Weil Gotshal & Manges LLP
BOARD OF DIRECTORS

Leonard A. Lauder, Co-Chairman

Ronald Lauder, Co-Chairman

Nancy Corzine, President

Howard Fillit, MD, Executive Director

Marti Dinerstein

Susan Roth Katzke

Jon W. Rotenstreich

Randal Bryan Sandler

Sally Susman

Joan Krupskas, Treasurer

Lisa Somar, Assistant Treasurer and Secretary

ADDF STAFF

Howard Fillit, MD
Executive Director

Nancy Lynn
Executive Vice President

Diane Duong
Executive Assistant, Operations Manager

Hannah Elkin
Development Assistant for Institutional Partnerships

Deb Gray
Senior Director of Advancement

Adam Liebling
Senior Grants Manager

Juan Licht
Office Manager

Filomena Machleder
Assistant Director for Institutional Partnerships

Dina Miller
Development Associate

Jackie Pirozzi
Development Assistant for Events

Allison Sawczyn
Assistant Director for Development

Diana Shineman, PhD
Assistant Director for Scientific Affairs

Niyati Thakker
Grants Assistant
Conquering Alzheimer’s Through Drug Discovery